Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)

NCT04720768 is registered in ClinicalTrials.gov with Peter MacCallum Cancer Centre, Australia as lead sponsor.

NCT NCT04720768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 4, 2020
Completion date
December 4, 2024
Enrollment
78 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, metastasis